Key Takeaways
- CELYSTRA Pharma announced on September 30 that Health Canada approved DAWNZERA for hereditary angioedema attack prevention in adults and pediatric patients aged 12 years and older.
- DAWNZERA contains donidalorsen, an RNA-targeted medicine designed to reduce plasma prekallikrein production, a protein involved in pathways associated with acute HAE attacks.
- The announced 80 mg treatment is administered through a pre-filled autoinjector once every four or eight weeks, providing two reported dosing intervals for eligible patients.
A New Preventive Treatment Option for HAE
Hereditary angioedema, or HAE, is a rare genetic disorder associated with recurrent episodes of swelling. Attacks can affect areas including the hands, feet, abdomen, face, throat and other parts of the body. Because episodes can occur unpredictably, prevention is an important part of long-term disease management.
According to CELYSTRA Pharma, the Health Canada approval allows DAWNZERA to be used specifically for preventing HAE attacks in patients 12 years of age and older.
How DAWNZERA Works
DAWNZERA contains donidalorsen, an RNA-targeted medicine developed to reduce the production of plasma prekallikrein, also known as PKK.
PKK plays a role in the biological pathway involved in activating inflammatory mediators associated with acute HAE attacks. By targeting the production of this protein, donidalorsen is designed to reduce activity within that pathway and support preventive treatment for people with HAE.
The treatment is administered through a subcutaneous injection using a single-dose pre-filled autoinjector. CELYSTRA says the 80 mg dose can be administered once every four weeks or once every eight weeks, depending on the prescribed dosing schedule.
CELYSTRA Expands Its Canadian Rare-Disease Portfolio
The DAWNZERA approval represents CELYSTRA Pharma's second Health Canada approval within nine months, according to the company's announcement.
The Montreal-based biopharmaceutical company focuses on bringing innovative therapies developed internationally to Canadian patients, particularly in areas involving specialized and unmet medical needs.
CELYSTRA previously received Health Canada approval for TRYNGOLZA (olezarsen), a treatment for familial chylomicronemia syndrome. The company licensed Canadian rights to both products from Ionis Pharmaceuticals.
Clinical Development Behind Donidalorsen
Donidalorsen has been studied in clinical programs involving people with hereditary angioedema. Ionis has reported Phase 3 OASIS-HAE and OASISplus data supporting development of the medicine as a preventive treatment.
Ionis describes DAWNZERA as an RNA-targeted prophylactic therapy for HAE in patients aged 12 years and older. The company's research program has also included studies examining long-term safety, efficacy and treatment outcomes in adolescents and other patient groups.
Canadian government clinical-trial records also list donidalorsen studies for hereditary angioedema, including the Phase 3 OASIS-HAE program.
TwikUp's Perspective
The significance of this development extends beyond the approval of another medicine. HAE is a condition where treatment decisions can involve both attack prevention and the practical burden of long-term therapy.
The availability of a treatment with reported four-week and eight-week dosing intervals could give physicians another factor to consider when developing preventive treatment plans for eligible patients. However, the appropriate treatment and dosing schedule remain clinical decisions that depend on individual patient circumstances.
For Canada's rare-disease landscape, the announcement also highlights the growing role of specialized therapies designed around specific biological pathways rather than broad treatment mechanisms.
What Comes Next
The September 30 announcement establishes DAWNZERA as a newly announced Health Canada-approved preventive treatment option for eligible Canadians aged 12 and older. Future access will depend on factors including commercialization, prescribing and Canada's broader drug-access and reimbursement processes.
For patients and healthcare professionals, the next stage will be understanding how DAWNZERA fits into existing HAE prevention strategies and how its availability affects treatment choices in Canadian clinical practice.